Regenxbio 2024年第四季度GAAP每股亏损$(1.01),优于预期的$(1.15);销售额为$2121万,不及预期的$2375万

财报速递
14 Mar
Regenxbio(NASDAQ:RGNX)报告季度每股亏损$(1.01),优于分析师预期的$(1.15),提高了12.17%。这一数字比去年同期每股亏损$(1.43)增长了29.37%。公司报告季度销售额为2121万美元,低于分析师预期的2375万美元,减少了10.69%。这一数字比去年同期的2221万美元减少了4.50%。

以上内容来自Benzinga Earnings专栏,原文如下:

Regenxbio (NASDAQ:RGNX) reported quarterly losses of $(1.01) per share which beat the analyst consensus estimate of $(1.15) by 12.17 percent. This is a 29.37 percent increase over losses of $(1.43) per share from the same period last year. The company reported quarterly sales of $21.21 million which missed the analyst consensus estimate of $23.75 million by 10.69 percent. This is a 4.50 percent decrease over sales of $22.21 million the same period last year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10